Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Common Equity (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Common Equity for 10 consecutive years, with $154.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 289.9% year-over-year to $154.7 million, compared with a TTM value of $154.7 million through Dec 2025, up 289.9%, and an annual FY2025 reading of $154.7 million, up 289.9% over the prior year.
  • Common Equity was $154.7 million for Q4 2025 at Zevra Therapeutics, up from $133.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $154.7 million in Q4 2025 and bottomed at -$7.5 million in Q3 2022.
  • Average Common Equity over 5 years is $78.6 million, with a median of $69.8 million recorded in 2024.
  • The sharpest move saw Common Equity crashed 105.72% in 2022, then surged 916.37% in 2023.
  • Year by year, Common Equity stood at $101.7 million in 2021, then decreased by 26.11% to $75.1 million in 2022, then dropped by 17.65% to $61.9 million in 2023, then plummeted by 35.88% to $39.7 million in 2024, then skyrocketed by 289.9% to $154.7 million in 2025.
  • Business Quant data shows Common Equity for ZVRA at $154.7 million in Q4 2025, $133.2 million in Q3 2025, and $117.2 million in Q2 2025.